Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.
The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL).
It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.83 Increased by +37.59% | -0.83 |
| Mar 7, 24 | -1.01 Increased by +15.13% | -1.03 Increased by +1.94% |
| Nov 13, 23 | -1.04 Increased by +21.21% | -1.21 Increased by +14.05% |
| Aug 3, 23 | -1.43 Decreased by -7.52% | -1.43 |
| May 12, 23 | -1.33 Increased by +13.07% | -1.36 Increased by +2.21% |
| Mar 30, 23 | -1.19 Increased by +20.67% | -1.25 Increased by +4.80% |
| Nov 3, 22 | -1.32 Increased by 0.00% | -1.43 Increased by +7.69% |
| Aug 8, 22 | -1.33 Decreased by -14.66% | -0.94 Decreased by -41.49% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 509.00 K Increased by +53.78% | -61.99 M Decreased by -11.57% | Decreased by -12.18 K% Increased by +27.45% |
| Jun 30, 23 | 448.00 K Increased by +22.40% | -64.42 M Decreased by -11.14% | Decreased by -14.38 K% Increased by +9.20% |
| Mar 31, 23 | 522.00 K Increased by +N/A% | -59.31 M Decreased by -14.43% | Decreased by -11.36 K% Decreased by N/A% |
| Dec 31, 22 | 372.00 K Increased by +N/A% | -48.20 M Increased by +4.83% | Decreased by -12.96 K% Decreased by N/A% |
| Sep 30, 22 | 331.00 K Increased by +N/A% | -55.56 M Decreased by -25.81% | Decreased by -16.79 K% Decreased by N/A% |
| Jun 30, 22 | 366.00 K Increased by +N/A% | -57.97 M Decreased by -49.73% | Decreased by -15.84 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -51.83 M Decreased by -63.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -50.64 M Decreased by -105.68% | Decreased by N/A% Decreased by N/A% |